Endocrinology
VEGF Trap creates reversible ovarian function inhibition in macaques
Published in Proteomics Weekly, April 11th, 2005
According to recent research from Scotland, "follicular development is associated with intense angiogenesis and increased permeability of blood vessels under the control of locally produced angiogenic factors such as vascular endothelial growth factor (VEGF). The aim of the present study was to evaluate the effects of transient inhibition of VEGF on pituitary-ovarian function in the macaque. Animals were given a single, i.v. injection of a potent, receptor-based VEGF antagonist, the VEGF Trap."
"VEGF Trap was given at a dose of 4, 1, or 0.25 mg/kg in the midfollicular phase or at...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Proteomics Weekly
Source: Proteomics Weekly (2005-04-11)
More Articles from Proteomics Weekly
- Disease Associations
Staphylococcal arthritis studied, role of fibronectin-binding factors shown - Drug Resistance
Chemokine patterns in meningococcal disease investigated - Matrix Metalloproteinase
Matrix metalloproteinases studied, roles in cardiac allograft rejection revealed - Muscular Dystrophy
Protein 4.1R expression in normal and dystrophic skeletal muscle investigated - Survivin
p21(Ras) studied, influence of survivin in human fibroblasts revealed - Actin
Scinderin analyzed, role as an actin molecular switch determined - More from this issue of Proteomics Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
